% | $
Quotes you view appear here for quick access.


  • analyst112 analyst112 Oct 20, 2011 3:33 PM Flag

    Options agreement

    They would not pay CYTO $2MM for an option without being pretty confident of CMS scheduling. CMS scheduling could mean $200MM of sales pretty fast especially with a this already established sales force (probably Abbot Labs). Chronic wounds are the most critical need in extended care and hospice. They will try anything new as long as Medicare pays for it. The best part is this product actually works to heal and relieve suffering. With approval, the stock should gap up to $3. Pretty good risk/reward. After a couple of years it will $10 and then sell to Abbot.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How often do we get to invest this early in a company with an FDA approved product at a $40MM valuation. This is as good as it gets. Cannot believe the stock is not $2 or $100MM valuation. The stock was $.60 in January and it has made quantum progress since then.